Aromatase inhibitors for breast cancer: pharmacoeconomic considerations

Bibliography

• GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer statistics, 2000. CA (2000) 50:7–33.
   Google Scholar
• HENDERSON IC, CANELLOS GP: Cancer of the breast. The past decade. N Engl. J. Med. (1980) 302:17–30.
   PubMed Web of Science ®Google Scholar
• •Provides overall perspective of the disease.
   Google Scholar
• JOHNSTON SR, SACCANI-JOTTI G, SMITH IE et al: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. (1995) 55:3331–3338.
   PubMed Web of Science ®Google Scholar
• •Demonstrates presence of the classic oestrogen receptor (ER-a) in normal and neoplastic tissue.
   Google Scholar
• THOMPSON EA, SIITERI PK: Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. j Biol. Chem. (1974) 249:5364–5372.
   PubMed Web of Science ®Google Scholar
• •Describes overall process of aromatisation.
   Google Scholar
• GRODIN JM, SIITERI PK, MACDONALD PC: Source of estrogenproduction in postmenopausal women. Chit. Endocnhol. Metab. (1973) 36:207–214.
   PubMed Web of Science ®Google Scholar
• SIEGELMANN-DANIELL N, ZHANG JQ, MCGLYNN KA, BUETOW KH: DNA-based variation at the aromatase gene (CYP19) and its role in breast cancer susceptibility. Proc. Am. Assoc. Cancer Res. (1996) 15:2002a. Abstract.
   Google Scholar
• SANTEN RJ, LESZCZYNSKI D, TILSON-MALLET N et al: Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulphatase pathways. Ann. NY Acad. Sri. (1986) 464:126–137.
   PubMed Web of Science ®Google Scholar
• KAUFMANN M, BAJETTA E, DIRIX LY etal.: Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: results of a double-blind randomized Phase III trial. Eur. j Cancer (2000) 36\(Suppl. 4):586–87.
   Google Scholar
• BAJETTA E, ZILEMBO N, BARNI S et al.: A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. Ann. Oncol. (1997) 8:649–654.
   PubMed Web of Science ®Google Scholar
• BUZDAR A, SMITH R, VOGEL C et al.:Fadrozole HC1 (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multi-institutional trials. Cancer (1996) 77:2503–2513.
   PubMed Web of Science ®Google Scholar
• JONAT W, HOWELL A, BLOMQVIST C et al.: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. Cancer (1996) 32A:404–412.
   PubMed Web of Science ®Google Scholar
• •Randomised trial comparing selective aromatase inhibitor versus progestin as second-line therapy.
   Google Scholar
• DOMBERNOWSKY P, SMITH I, FALKSON G et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Cilia. Once] (1998) 16:453–461.
   PubMed Web of Science ®Google Scholar
• •Randomised trial comparing selective aromatase inhibitor versus progestin as second-line therapy.
   Google Scholar
• GOSS PE, WINER EP, TANNOCK IF, SCHWARTZ LH: Randomized Phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J. Gun. Oncol. (1999) 17:52–63.
   Google Scholar
• •Randomised trial comparing selective aromatase inhibitor versus progestin as second-line therapy.
   Google Scholar
• WILLIAMS CJ: Is health economics useful in cancer? Crit. Rev Once]. Heinatel. (1999) 30:25–33.
   PubMed Web of Science ®Google Scholar
• •Appraisal of economic analyses in decision making for cancer care.
   Google Scholar
• KESTELOOT K: Predicting the future health care expenses of cancer. Eur J. Cancer (1994) 30A:3–5.
   PubMed Web of Science ®Google Scholar
• •Comments on the use of cost-effectiveness analyses.
   Google Scholar
• NCI-ASCO ECONOMICS WORKING GROUP: Integrating economic analysis into cancer clinical trials: the National Cancer Institute. J. Natl. Cancer Inst. Motiog. (1998) 24:1–28.
   Google Scholar
• ••Paper provides detailed descriptions of costcategories.
   Google Scholar
• FRIEDBERG M, SAFFRAN B, STINSON TJ, NELSON W, BENNETT CL: Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA (1999) 282:1453–1457.
   PubMed Web of Science ®Google Scholar
• •Focus of paper on conflict of interest on health economics.
   Google Scholar
• MCGUIRE WL: Steroid receptors in human breast cancer. Cancer Res. (1978) 38:4289–4291.
   PubMed Web of Science ®Google Scholar
• ••Analyses the predictive value of quantitative oestrogen receptors levels.
   Google Scholar
• HOROBIN JM, PREECE PE, DEWAR JA, WOOD RA, CUSCHIERI A: Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J. Surg. (1991) 78:213–217.
   PubMed Web of Science ®Google Scholar
• AHMANN DL, GREEN SJ, BISEL HF et al.: An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy: a later analysis. Ain. J. Clin. Oncol. (1982) 5:355–358.
   PubMed Web of Science ®Google Scholar
• TAYLOR SG, GELMAN RS, FALKSON G et al.: Combination chemotherapy compared to tamoxifen as initial therapy for stage II breast cancer in elderly women. Ann. Intern. Med. (1986) 104:455–461.
   PubMed Web of Science ®Google Scholar
• •Observed outcomes relative to treatment regimen.
   Google Scholar
• AUSTRALIAN AND NEW ZEALAND BREAST CANCER TRIALS GROUP. CLINICAL ONCOLOGICAL SOCIETY OF AUSTRALIA: A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J. Clin. Once]. (1986) 4:186–193.
   PubMed Web of Science ®Google Scholar
• •Objective data of treatment-related outcomes.
   Google Scholar
• HENDERSON IC: Endocrine therapy of metastatic breast cancer. Breast Dis. (1991) 2:559–603.
   Google Scholar
• NABHOLTZ JM, BUZDAR A, POLLAK M et al.: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Gun. Once]. (2000) 18:3758–3767.
   PubMed Web of Science ®Google Scholar
• •Randomised trial comparing selective aromatase inhibitor versus tamoxifen as first-line therapy.
   Google Scholar
• BONNETERRE J, THURLIMANN B, ROBERTSON JFR et al.: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J. Clin. Oncol. (2000) 18:3748–3757.
   PubMed Web of Science ®Google Scholar
• •Randomised trial comparing selective aromatase inhibitor versus tamoxifen as first-line therapy.
   Google Scholar
• BULUN SE, SIMPSON ER: Regulation of aromatase expression in human tissues. Breast Cancer Res. Treat. (1994) 30:19–29.
   PubMed Web of Science ®Google Scholar
• •Expression of aromatase in malignant breast tissue.
   Google Scholar
• SANTEN RJ, SAMOJLIK E, WELLS SA:Resistance of the ovary to blockade of aromatization with aminoglutethimide. Gun. Endocrine]. Metall. (1980) 51:473–477.
   PubMed Web of Science ®Google Scholar
• BUZDAR AU, JONAT W, HOWELL A et al.: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Arimidex study group. Cancer (1998) 83:1142–1152.
   Google Scholar
• ••Demonstration of survival benefitfavouring aromatase inhibitor as second-line therapy.
   Google Scholar
• WRIGHT T: Anastrozole cost effective in advanced breast cancer. PharinacoEcon. Outcomes News (1998) 147:3–4.
   Google Scholar
• HILLNER BE, RADICE DAVIDE: Cost-effectiveness analysis of exemestane compared with megestrol acetate in patients with advanced breast carcinoma. Cancer (2001) 91:484–489.
   PubMed Web of Science ®Google Scholar
• JORDAN VC: Chemotherapy is antihormonal therapy-how much proof do oncologists need? Eur J. Cancer (1998) 34:606–608.
   Web of Science ®Google Scholar
• FISHER B, REDMOND C, FISHER ER et au.: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl. J. Med. (1985) 312:674–681.
   Google Scholar
• ••Advances in surgical management ofbreast cancer.
   Google Scholar
• FISHER B, FISHER ER, REDMOND C: Ten year results from the NSABP clinical trial evaluating the use of 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J. Gun. Once]. (1986) 4:929–941.
   PubMed Web of Science ®Google Scholar
• ••Paper demonstrates benefits of adjuvantsystemic chemotherapy.
   Google Scholar
• BONADONNA G, VALAGUSSA P, ROSSI A et al.: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res. Treat. (1985) 5:95–115.
   PubMed Web of Science ®Google Scholar
• ••Paper demonstrates benefits of adjuvantsystemic chemotherapy.
   Google Scholar
• LUDWIG BREAST CANCER STUDY GROUP: A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res. (1985) 45:4454–4459.
   PubMed Web of Science ®Google Scholar
• •Data suggest antitumour effects related to oestrogen deprivation.
   Google Scholar
• EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Ovarian ablation in early breast cancer: an overview of randomized trials. Lancet (1996) 348:1189–1196.
   PubMed Web of Science ®Google Scholar
• •Data supporting oestrogen deprivation as an antitumour mechanism.
   Google Scholar
• EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet (1998) 351:451–466.
   Web of Science ®Google Scholar
• ••Meta-analyses demonstrating significantbenefits of anti-oestrogen therapy.
   Google Scholar
• HOUGHTON J, BAUM M: Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer. Eur. J. Cancer (1998) 34\(Suppl. 5):S83. Abstract.
   Google Scholar
• EDDY DM, HASSELBLAD V, MCGIVNEY W, HENDEE W: The value of mammography screening in women under age 50 years. JAMA (1988) 259:1512–1519.
   PubMed Web of Science ®Google Scholar
• ••Estimates benefits, risks, and costs ofmammography on individuals and society.
   Google Scholar
• SHAPIRO S, VENET W, STRAX E VENET L, ROESER R: Ten-to-fourteen-year effect of screening on breast cancer mortality. J. Nati Cancer Inst. (1982) 69:349–355.
   PubMed Web of Science ®Google Scholar
• ••Data demonstrate benefits of breast cancerscreening.
   Google Scholar
• BEAR HD: Indications for neoadjuvant chemotherapy for breast cancer. &min. Oncol. (1998) 25\(Suppl. 3):3–12.
   Google Scholar
• FISHER B, BAUER M, MARGOLESE R et al.: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl. J. Med. (1985) 312:666–673.
   Web of Science ®Google Scholar
• ••Study demonstrating outcomes not relatedto extent of surgical intervention.
   Google Scholar
• KEEN JC, DIXON JM, MILLER EP et al.: The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res. Treat (1997) 44:123–133.
   PubMed Web of Science ®Google Scholar
• •Study demonstrating effect of pre-surgical endocrine therapy on tumour volume.
   Google Scholar
• CAVALIERI EL, STACK DE, DEVANESAN PD et al.: Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Nati Acad. Sci. USA (1997) 94:10937–10942.
   PubMed Web of Science ®Google Scholar
• •Report suggesting oestrogens act early in carcinogenesis.
   Google Scholar
• LAVIGNE JA, HELZLSOUER KJ, HUANG HY et al.: An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res. (1997) 57:5493–5497.
   PubMed Web of Science ®Google Scholar
• •Data showing role of oestrogens as genotoxic compounds.
   Google Scholar
• ALLRED DC, O'CONNELL E FUQUA SAW: Biomarkers in early breast neoplasia. J. Cell. Biochem. Suppl. (1993) 17G:125–131.
   PubMedGoogle Scholar
• JORDAN VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA induced rat mammary carcinomata. Eur. Cancer (1975) 12:419–424.
   Web of Science ®Google Scholar
• •Data supporting efficacy of early intervention with hormonal therapy.
   Google Scholar